Islet autoimmunity in phenotypic type 2 diabetes patients

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 137-140

  Brooks Worrell, B ^a   Narla, R ^b   Palmer, J P ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Autoimmune disease; Autoimmunity; Inflammation; Islet reactive T cells; T cells; Type 1 diabetes; Type 2 diabetes

Indexed keywords

AUTOANTIBODY; GLIBENCLAMIDE; ROSIGLITAZONE;

AUTOIMMUNE DISEASE; DISEASE MARKER; EFFECTOR CELL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOGENESIS; REVIEW; T LYMPHOCYTE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; INFLAMMATION; ISLET-REACTIVE T CELLS; T CELLS; TYPE 1 DIABETES; TYPE 2 DIABETES;

AUTOANTIBODIES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS; PHENOTYPE; T-LYMPHOCYTES;

EID: 84883544557     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12167     Document Type: Review

References (34)

1. Brooks-Worrell B, Palmer JP. Is diabetes mellitus a continuous spectrum? Clin Chem 2011; 57: 158-161.
2. Merger SR, Leslie RD, Boehm BO. The broad clinical phenotype of type 1 diabetes at presentation. Diabet Med 2013; 30: 170-178.
3. Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients: respond to multiple islet cell proteins. J Immunol 1996; 157: 5668-5674.
4. Nokoff N, Rewers M. Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann N Y Acad Sci 2013; 1281: 1-15.
5. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001; 166: 5265-5270.
6. Seyfert-Margolis V, Gisler TD, Asare AL et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006; 55: 2588-2594.
7. Herold KC, Brooks-Worrell B, Palmer JP et al. Validity and reproducibility of measurement of islet autoreactivity by T cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58: 2588-2595.
8. Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods 2009; 344: 79-83.
9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
10. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009; 115: 240-247.
11. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008; 31(Suppl. 2): S161-S164.
12. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 2009; 4: 325-331.
13. Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 2003; 52: 812-817.
14. Kalupahana NS, Moustaid-Moussa N, Claycomb KJ. Immunity as a link between obesity and insulin resistance. Mol Aspects Med 2012; 33: 26-34.
15. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1050.
16. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
17. Festa A, D'Agostino RR, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
18. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
19. Pradhan DA, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
20. Brooks-Worrell B, Palmer JP. Clinical immunology review series: focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167: 40-46.
21. Fourlanos S, Dotta F, Greenbaum CJ et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206-2212.
22. Turner R, Stratton I, Horton V et al. UKPDS 25: autoantibodies in islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-1293.
23. Tuomi T, Groop L, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362.
24. Zimmet P, Tuomi T, Mackay I et al. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11: 299-303.
25. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56: 2110-2115.
26. Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune response to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48: 983-988.
27. Groop L, Botazzo GF, Koniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75years at diagnosis. Diabetes 1986; 35: 237-241.
28. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies but not the clinical phenotype help to identify type 1 1/2 diabetes in patients presenting with type 2 diabetes. Metabolism 2001; 50: 1008-1013.
29. Brooks-Worrell BM, Greenbaum CJ, Palmer JP, Pihoker C. Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab 2004; 89: 2222-2227.
30. Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetes patients. Diabetes Care 2011; 34: 168-173.
31. Wang J, Miao D, Babu S et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007; 92: 88-92.
32. Brooks-Worrell B, Ismail H, Wotring M, Kimmie C, Felton J, Palmer JP. Autoimmune development in phenotypic type 2 diabetes patients. Clin Immunol 2007; 123: S66-S67.
33. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54: S62-S67.
34. Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013; 171: 164-170.